This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A compound 8 to 50 nucleobases in length targeted to the 3' untranslated region of a nucleic acid molecule encoding TGF-â2 (SEQ ID NO:47), ~~wherein said compound comprises at least a portion of a sequence selected from the group consisting of SEQ ID NO:53, 54, 55, 56, 58, 60, 61, 62, 63, 64, 65, 66 or 69, and~~ wherein said compound modulates the expression of TGF-â2.

Claim 2 (original): The compound of claim 1 which is an antisense oligonucleotide.

Claim 3 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

Claim 4 (original): The compound of claim 3 wherein the modified internucleoside linkage of the antisense oligonucleotide is a phosphorothioate linkage.

Claim 5 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

Claim 6 (original): The compound of claim 5 wherein the modified sugar moiety of the antisense oligonucleotide is a 2'-O-methoxyethyl sugar moiety.

Claim 7 (original): The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

Claim 8 (original): The compound of claim 7 wherein the modified nucleobase of the antisense oligonucleotide is a 5-methylcytosine.

Claim 9 (original): The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Claim 10 (original): A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

Claim 11 (original): The composition of claim 10 further comprising a colloidal dispersion system.

Claim 12 (original): The composition of claim 10 wherein the compound is an antisense oligonucleotide.

Claim 13 (original): A method of inhibiting the expression of TGF-â2 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of TGF-â2 is inhibited.

Claim 14 (original): A method of treating an animal having a disease or condition associated with TGF-â2 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of TGF-â2 is inhibited.

Claim 15 (original): The method of claim 14 wherein said disease or condition is inflammation.

Claim 16 (original): The method of claim 14 wherein said disease or condition is fibrosis or a fibrotic disease or condition.

Claim 17 (original): The method of claim 16, wherein said fibrotic disease or condition is fibrotic scarring, peritoneal adhesions, lung fibrosis or conjunctival scarring.